Merck & Co. Inc. [NYSE: MRK] traded at a low on 08/07/20, posting a -0.04 loss after which it closed the day’ session at $81.02. The company report on August 5, 2020 that Merck Animal Health Completes Acquisition of IdentiGEN.
Strategic Transaction Enhances Farm-to-Table Animal Traceability Solutions for Livestock and Aquaculture.
Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its acquisition of IdentiGEN, a leader in DNA-based animal traceability solutions for Livestock and Aquaculture from MML Growth Capital Partners Ireland. Specific terms of the agreement were not disclosed.
The results of the trading session contributed to over 6656088 shares changing hands. Over the past one week, the price volatility of Merck & Co. Inc. stands at 1.86% while the volatility over the past one month is 1.91%.
The market cap for MRK stock reached $204.58 billion, with 2.53 billion shares outstanding and 2.52 billion shares in the current float. Compared to the average trading volume of 9.69M shares, MRK reached a trading volume of 6656088 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Merck & Co. Inc. [MRK]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRK shares is $94.41 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRK stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Merck & Co. Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 03, 2020. The new note on the price target was released on June 12, 2020, representing the official price target for Merck & Co. Inc. stock. Previously, the target price had yet another raise to $93, while Barclays analysts kept a Overweight rating on MRK stock.
The Average True Range (ATR) for Merck & Co. Inc. is set at 1.65, with the Price to Sales ratio for MRK stock in the period of the last 12 months amounting to 4.33. The Price to Book ratio for the last quarter was 7.41, with the Price to Cash per share for the same quarter was set at 4.40. Price to Free Cash Flow for MRK in the course of the last twelve months was 59.87 with Quick ratio for the last quarter at 1.10.
How has MRK stock performed recently?
Merck & Co. Inc. [MRK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.97. With this latest performance, MRK shares gained by 5.65% in over the last four-week period, additionally sinking by -4.77% over the last 6 months – not to mention a drop of -4.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRK stock in for the last two-week period is set at 54.71, with the RSI for the last a single of trading hit 58.78, and the three-weeks RSI is set at 55.61 for Merck & Co. Inc. [MRK]. The present Moving Average for the last 50 days of trading for this stock 78.84, while it was recorded at 81.58 for the last single week of trading, and 81.91 for the last 200 days.
Merck & Co. Inc. [MRK]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Merck & Co. Inc. [MRK] shares currently have an operating margin of +28.62 and a Gross Margin at +70.25. Merck & Co. Inc.’s Net Margin is presently recorded at +21.13.
Return on Total Capital for MRK is now 25.31, given the latest momentum, and Return on Invested Capital for the company is 20.52. Return on Equity for this stock inclined to 37.42, with Return on Assets sitting at 11.79. When it comes to the capital structure of this company, Merck & Co. Inc. [MRK] has a Total Debt to Total Equity ratio set at 105.57. Additionally, MRK Total Debt to Total Capital is recorded at 51.35, with Total Debt to Total Assets ending up at 32.41. Long-Term Debt to Equity for the company is recorded at 90.72, with the Long-Term Debt to Total Capital now at 44.13.
Reflecting on the efficiency of the workforce at the company, Merck & Co. Inc. [MRK] managed to generate an average of $138,634 per employee. Receivables Turnover for the company is 6.73 with a Total Asset Turnover recorded at a value of 0.56.Merck & Co. Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.
Earnings analysis for Merck & Co. Inc. [MRK]
With the latest financial reports released by the company, Merck & Co. Inc. posted 1.51/share EPS, while the average EPS was predicted by analysts to be reported at 1.24/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Merck & Co. Inc. go to 6.25%.
Insider trade positions for Merck & Co. Inc. [MRK]
There are presently around $155,233 million, or 77.80% of MRK stock, in the hands of institutional investors. The top three institutional holders of MRK stocks are: VANGUARD GROUP INC with ownership of 216,995,472, which is approximately 3.065% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 196,345,328 shares of the stock with an approximate value of $15.91 billion in MRK stocks shares; and STATE STREET CORP, currently with $9.51 billion in MRK stock with ownership of nearly 0.729% of the company’s market capitalization.
Positions in Merck & Co. Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,269 institutional holders increased their position in Merck & Co. Inc. [NYSE:MRK] by around 92,303,493 shares. Additionally, 1,074 investors decreased positions by around 114,474,914 shares, while 276 investors held positions by with 1,709,207,026 shares. The mentioned changes placed institutional holdings at 1,915,985,433 shares, according to the latest SEC report filing. MRK stock had 125 new institutional investments in for a total of 3,771,687 shares, while 139 institutional investors sold positions of 5,350,875 shares during the same period.